The current study indicated that ACSL4 as a biomarker may be useful for predicting outcomes of patients after immunotherapeutic treatments and may have important translational impacts in the development of precise therapy for BLCA. This evidence concerns the gene ACSL4 and bladder transitional cell carcinoma.